Population pharmacokinetics of artemether, lumefantrine, and their respective metabolites in papua new guinean children with uncomplicated malaria

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 11, 2011, Pages 5306-5313

  Salman, Sam ^a   Page Sharp, Madhu ^b   Griffin, Susan ^c   Kose, Kaye ^c   Siba, Peter M ^c   Ilett, Kenneth F ^a   Mueller, Ivo ^c,d   Davis, Timothy M E ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b CURTIN UNIVERSITY   (Australia)

^c PAPUA NEW GUINEA INSTITUTE OF MEDICAL RESEARCH   (Papua New Guinea)

^d CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER; BENFLUMETOL; DIHYDROARTEMISININ; DRUG METABOLITE;

AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HUMAN; MALARIA FALCIPARUM; MALE; PAPUA NEW GUINEA; PLASMODIUM MALARIAE INFECTION; PLASMODIUM OVALE MALARIA; PLASMODIUM VIVAX MALARIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SCHOOL CHILD;

ANTIMALARIALS; ARTEMISININS; CHILD; CHILD, PRESCHOOL; ETHANOLAMINES; FEMALE; FLUORENES; HUMANS; MALARIA; MALE;

EID: 80054684538     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05136-11     Document Type: Article

References (35)

1. Abdulla, S., et al. 2008. Efficacy and safety of artemether-lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multicentre trial. Lancet 372:1819-1827.
2. Ahn, J. E., M. O. Karlsson, A. Dunne, and T. M. Ludden. 2008. Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J. Pharmacokinet. Pharmacodyn. 35:401-421.
3. Anderson, B. J., and N. H. Holford. 2008. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu. Rev. Pharmacol. Toxicol. 48:303-332. (Pubitemid 351738156)
4. Ashley, E. A., et al. 2007. How much fat is necessary to optimize lumefantrine oral bioavailability? Trop. Med. Int. Health 12:195-200.
5. Ashley, E. A., et al. 2007. Pharmacokinetic study of artemether- lumefantrine given once daily for the treatment of uncomplicated multidrug-resistant falciparum malaria. Trop. Med. Int. Health 12:201-208.
6. Barnes, K. I., et al. 2006. Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. Clin. Pharmacol. Ther. 80:582-596. (Pubitemid 44920218)
7. Batty, K. T., et al. 1996. Selective high-performance liquid chromatographic determination of artesunate and alpha- and beta- dihydroartemisinin in patients with falciparum malaria. J. Chromatogr. B Biomed. Appl. 677:345-350. (Pubitemid 26106005)
8. Bell, D. J., et al. 2011. Population pharmacokinetics of sulfadoxine and pyrimethamine in Malawian children with malaria. Clin. Pharmacol. Ther. 89:268-275.
9. Bergstrand, M., and M. O. Karlsson. 2009. Handling data below the limit of quantification in mixed effect models. AAPS J. 11:371-380.
10. Bergstrand, M., E. Plan, M. C. Kjellsson, and M. O. Karlsson. 2007. A comparison of methods for handling of data below the limit of quantification in NONMEM VI, abstr. 1201. Abstr. 16th Annu. Meet. Popul. Approach Group Eur., Copenhagen, Denmark, 13 to 15 June 2007. http://www.page-meeting.org/pdf-assets/ 6427-Poster-PAGE2007-070607-final.pdf.
11. Bindschedler, M., et al. 2000. Cardiac effects of co-artemether (artemether/lumefantrine) and mefloquine given alone or in combination to healthy volunteers. Eur. J. Clin. Pharmacol. 56:375-381.
12. Ezzet, F., R. Mull, and J. Karbwang. 1998. Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients. Br. J. Clin. Pharmacol. 46:553-561. (Pubitemid 28522119)
13. Ezzet, F., M. van Vugt, F. Nosten, S. Looareesuwan, and N. J. White. 2000. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob. Agents Chemother. 44:697-704. (Pubitemid 30117964)
14. German, P., et al. 2009. Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. J. Acquir. Immune Defic. Syndr. 51:424-429.
15. Hatz, C., et al. 2008. Treatment of acute uncomplicated falciparum malaria with artemether-lumefantrine in nonimmune populations: a safety, efficacy, and pharmacokinetic study. Am. J. Trop. Med. Hyg. 78:241-247. (Pubitemid 351844558)
16. Hietala, S. F., et al. 2010. Population pharmacokinetics and pharmacodynamics of artemether and lumefantrine during combination treatment in children with uncomplicated falciparum malaria in Tanzania. Antimicrob. Agents Chemother. 54:4780-4788.
17. Hooker, A. C., C. E. Staatz, and M. O. Karlsson. 2007. Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm. Res. 24:2187-2197. (Pubitemid 350060706)
18. Karunajeewa, H. A., et al. 2008. A trial of combination antimalarial therapies in children from Papua New Guinea. N. Engl. J. Med. 359:2545-2557.
19. Lefevre, G., et al. 2002. Interaction trial between artemether- lumefantrine (Riamet) and quinine in healthy subjects. J. Clin. Pharmacol. 42:1147-1158.
20. Lefevre, G., et al. 2002. Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects. Br. J. Clin. Pharmacol. 54:485-492. (Pubitemid 35356874)
21. Lefevre, G., et al. 2001. A clinical and pharmacokinetic trial of six doses of artemether-lumefantrine for multidrug-resistant Plasmodium falciparum malaria in Thailand. Am. J. Trop. Med. Hyg. 64:247-256.
22. Lefevre, G., and M. S. Thomsen. 1999. Clinical pharmacokinetics of artemether and lumefantrine (Riamet (R)). Clin. Drug Investig. 18:467-480. (Pubitemid 30047534)
23. Matuszewski, B. K., M. L. Constanzer, and C. M. Chavez-Eng. 2003. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal. Chem. 75:3019-3030. (Pubitemid 36830428)
24. McGready, R., et al. 2006. The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria. Eur. J. Clin. Pharmacol. 62:1021-1031. (Pubitemid 44786494)
25. Mwesigwa, J., et al. 2010. Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda. Antimicrob. Agents Chemother. 54:52-59.
26. Noedl, H., T. Allmendinger, S. Prajakwong, G. Wernsdorfer, and W. H. Wernsdorfer. 2001. Desbutyl-benflumetol, a novel antimalarial compound: in vitro activity in fresh isolates of Plasmodium falciparum from Thailand. Antimicrob. Agents Chemother. 45:2106-2109. (Pubitemid 32591705)
27. Price, R. N., et al. 2006. Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin. Infect. Dis. 42:1570-1577.
28. Starzengruber, P., et al. 2008. Interaction between lumefantrine and monodesbutyl-benflumetol in Plasmodium falciparum in vitro. Wien. Klin. Wochenschr. 120:85-89.
29. Starzengruber, P., et al. 2007. Specific pharmacokinetic interaction between lumefantrine and monodesbutyl-benflumetol in Plasmodium falciparum. Wien. Klin. Wochenschr. 119:60-66. (Pubitemid 350094907)
30. Tarning, J., et al. 2009. Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria. Antimicrob. Agents Chemother. 53:3837-3846.
31. van Agtmael, M. A., S. Cheng-Qi, J. X. Qing, R. Mull, and C. J. van Boxtel. 1999. Multiple dose pharmacokinetics of artemether in Chinese patients with uncomplicated falciparum malaria. Int. J. Antimicrob. Agents 12:151-158. (Pubitemid 29276919)
32. Wong, R. P. M., et al. 2011. Desbutyl-lumefantrine is a metabolite of lumefantrine with potent in vitro antimalarial activity that may influence artemether-lumefantrine treatment outcome. Antimicrob. Agents Chemother. 55:1194-1198.
33. World Health Organization. 2010. World malaria report. World Health Organization, Geneva, Switzerland.
34. World Health Organization, Communicable Diseases Cluster. 2000. Severe falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 94(Suppl. 1):S1-S90.
35. Yang, S., and J. Roger. 2010. Evaluations of Bayesian and maximum likelihood methods in PK models with below-quantification-limit data. Pharm. Stat. 9:313-330.